JAK2 and essential thrombocythemia: In line with existing pediatric literature, we observed a lower percentage of JAK2 V617F-positive patients [5, 8, 9], 35% (6/17), with variable allelic frequencies (ranging from 3.44 to 51.4%) in ET and PV, respectively [5, 8, 9].